SURVIVEDipatasertib akt1

Ipatasertib → AKT1 (PI3Kα→AKT1 axis node)

What we’re testing

target · AKT1

Mechanism. Ipatasertib (GDC-0068) is an ATP-competitive AKT inhibitor. AKT1 is the surviving synthetic-lethal co-dependency of PIK3CA-mutant cells (DepMap 24Q4). This docking test scores pocket engagement on the verified AKT1 receptor; an approved AKT inhibitor binding AKT1 is expected — the value is establishing the dockable PI3Ka->AKT1 axis node for future novel-modality bets, not a surprising result.

Where it stands — still standing

Survived every test the engine could run. Nothing here is proven — that's the point.

Status on the engine: evidence supported · validation-ready. Nothing here is promoted automatically — a human holds the final call.

Follow the trail

See the evidence →1 test

the pre-registered tests, verdict, and signed provenance

View the run →

the campaign that tested this idea — Falsification campaign — 5 candidate(s), runner=modal

Grounded in

DepMap:24Q4 AKT1 co-dependency of PIK3CA-mutPDB:4EKLtarget_library:AKT1 (redock 1.829A)

How we know it’s real

content-addressed · d1fa2fbf8031e068…updated 2026-07-13

Every idea and every result is hashed so anyone can re-derive it. Want a drug or target put to the test? Suggest one →

Contribute to this idea

Have evidence, a critique, a replication, or compute to add? When contributor check-in is open you can submit a bounded packet — queued for human review, and it never changes the record on its own.

Checking whether check-in is open…